COPALIS MULTIPLEX EBV ANTIBODY ASSAY— 510(k) K991660
Substantially EquivalentDiaSorin, Inc.
FDA 510(k) clearance K991660 for COPALIS MULTIPLEX EBV ANTIBODY ASSAY, Substantially Equivalent on 1999-06-04. Applicant: DiaSorin, Inc.. Device class: 1.
Clearance details
- Applicant
- DiaSorin, Inc.
- Product code
- Code LSE
- Device class
- Class 1
- Regulation
- 21 CFR 866.3235
- Advisory panel
- Microbiology
- Date received
- Decision date
- Decision
- Substantially Equivalent
- Clearance type
- Traditional
- Location
- Columbia, MD, US
Recent devices under product code LSE
view all- K233606 — ADVIA Centaur EBV-VCA IgM
- K162961 — LIAISON® VCA IgG and LIAISON® VCA IgG Serum Control Set; LIAISON® EBNA IgG and LIAISON® EBNA IgG Serum Control Set
- K162959 — LIAISON® EA IgG and LIAISON® EA IgG Serum Control Set
- K091260 — SERAQUEST EBV EA-D IGG TEST
- K073382 — PLEXUS EBV IGG MULTI-ANALYTE DIAGNOSTICS, MODEL: MP0500G
More clearances from DiaSorin, Inc.
view all- K260770 — LIAISON Murex HBsAg Qual; LIAISON XL; LIAISON diluteX
- DEN250032 — LIAISON® XL MUREX Anti-HDV (318260); LIAISON® XL MUREX Control Anti-HDV (318261)
- K231214 — LIAISON VZV IgG HT, LIAISON Control VZV IgG HT
- K223403 — LIAISON Anti-HAV; LIAISON XS
- K213858 — LIAISON Calprotectin, LIAISON Q.S.E.T. Device Plus
Data sourced from openFDA. This site is unofficial and independent of the FDA.